Journals / Turkish journal of nephrology (Online) / 2022 / Cilt: 31 - Sayı: 2

Could Peritoneal Dialysis be an Option for the Treatment of Congestive Heart Failure?

Pages
155–164
Publication Date
2022-11-05
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

Conclusion: In heart failure patients with reduced ejection fraction with diuretic resistance, peritoneal dialysis improves congestive symptoms, improves functional capacity, and offers a treatment option in addition to pharmacological therapy.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Heart failure is a progressive and fatal disease even with appropriate treatment.
📊
Key Findings & Data:Methods: The 2-year follow-up data of 12 heart failure patients with reduced ejection fraction who had undergone peritoneal dialysis at our center between 2014 and 2019 were retrospectively analyzed in 3-month periods.
💡
Conclusion & Impact:Conclusion: In heart failure patients with reduced ejection fraction with diuretic resistance, peritoneal dialysis improves congestive symptoms, improves functional capacity, and offers a treatment option in addition to pharmacological therapy.
🔬Design:Research Article
📍Scope:2014 Verileri
⚙️Variables:Domain Parameters

Abstract

Objective: Heart failure is a progressive and fatal disease even with appropriate treatment. Hypervolemia is a major cause of mortality and hospital admissions in these patients. Peritoneal dialysis has been successfully used for volume control in congestive heart failure patients with diuretic resistance in recent years. The present study aims to assess the effects of peritoneal dialysis on refractory heart failure. Methods: The 2-year follow-up data of 12 heart failure patients with reduced ejection fraction who had undergone peritoneal dialysis at our center between 2014 and 2019 were retrospectively analyzed in 3-month periods. The effects of peritoneal dialysis on functional status, echocardiography, physical and biochemical parameters, hospital admission, and mortality rates were assessed. Results: Functional capacity improved significantly (P = .005). When the sixth month was reached, no patient remained in the New York Heart Association class 4. A significant improvement was observed in mean arterial pressure (75.3 ± 17 vs. 91.3 ± 16.6; P = .005). There was an improvement in congestive symptoms (dyspnea, pleural effusion, and pretibial edema; P = .037; P = .0002; P = .005, respectively). Although statistical significance could not be reached, ejection fraction on echocardiography was found to increase (28.7% ± 12% vs. 37% ± 12%; P = .113). Despite statistical significance was not reached, there was a trend for an increase in hematocrit, serum albumin, and sodium levels and a decrease in uric acid level. The 1-year and 2-year mortality rates were 41.7% and 58.3%, respectively. Conclusion: In heart failure patients with reduced ejection fraction with diuretic resistance, peritoneal dialysis improves congestive symptoms, improves functional capacity, and offers a treatment option in addition to pharmacological therapy.

🔖

Cite This Article

HUDDAM, B., ALP, A., GENEK, D. G. (2022). Could Peritoneal Dialysis be an Option for the Treatment of Congestive Heart Failure?. Turkish journal of nephrology (Online), Cilt: 31 - Sayı: 2, 155–164. https://ajindex.com/articles/612823

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Groenewegen A, Rutten FH, Mosterd A, Hoes AW. Epidemiology of heart failure. Eur J Heart Fail. 2020
  2. 22(8):1342-1356. [CrossRef] 2. Shah KS, Xu H, Matsouaka RA, et al. Heart failure with preserved, borderline, and reduced ejection fraction: 5-year outcomes. J Am Coll Cardiol. 2017
  3. 70(20):2476-2486. [CrossRef] 3. Kazory A, Bargman JM. Defining the role of peritoneal dialysis in management of congestive heart failure. Expert Rev Cardiovasc Ther. 2019
  4. 17(7):533-543. [CrossRef] 4. Kazory A. Peritoneal dialysis for chronic cardiorenal syndrome: lessons learned from ultrafiltration trials. World J Cardiol. 2015
  5. 7(7):392-396. [CrossRef] 5. Puttagunta H, Holt SG. Peritoneal dialysis for heart failure. Perit Dial Int. 2015
  6. 35(6):645-649. [CrossRef] 6. François K, Ronco C, Bargman JM. Peritoneal dialysis for chronic congestive heart failure. Blood Purif. 2015
  7. 40(1):45-52. [CrossRef] 7. Courivaud C, Kazory A, Crépin T, et al. Peritoneal dialysis reduces the number of hospitalization days in heart failure patients refractory to diuretics. Perit Dial Int. 2014
  8. 34(1):100-108. [CrossRef] 8. Zemel D, Imholz AL, de Waart DR, Dinkla C, Struijk DG, Krediet RT. Appearance of tumor necrosis factor-alpha and soluble TNFreceptors I and II in peritoneal effluent of CAPD. Kidney Int. 1994
  9. 46(5):1422-1430. [CrossRef] 9. Chiarelli G, Beaulieu M, Taylor P, Levin A, Holmes DT. Elimination of BNP by peritoneal dialysis: investigationof analytical issues. Perit Dial Int. 2011
  10. 31(2):199-202. [CrossRef] 10. Yancy CW, Jessup M, Bozkurt B, et al. 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines. J Am Coll Cardiol. 2013
  11. 62(16):e147-e239. [CrossRef] 11. Neuberg GW, Miller AB, O’Connor CM, et al. Diuretic resistance predicts mortality in patients with advanced heart failure. Am Heart J. 2002
  12. 144(1):31-38. [CrossRef] 12. Koch M, Haastert B, Kohnle M, et al. Peritoneal dialysis relieves clinical symptoms and is well tolerated in patients with refractory heart failure and chronic kidney disease. Eur J Heart Fail. 2012
  13. 14(5):530-539. [CrossRef] 13. Bertoli SV, Musetti C, Ciurlino D, et al. Peritoneal ultrafiltration in refractory heart failure: a cohort study. Perit Dial Int. 2014
  14. 34(1):64- 70. [CrossRef] 14. Ponce D, Góes C, Oliveira M, Balbi A. Peritoneal dialysis for the treatment of cardiorenal syndrome type 1: a prospective Brazilian study. Perit Dial Int. 2017